Meibomian Gland Dysfunction Market Outlook 2025-2035:
The 7 major meibomian gland dysfunction market reached a value of USD 2.2 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 4.9 Billion by 2035, exhibiting a growth rate (CAGR) of 7.37% during 2025-2035. The market for meibomian gland dysfunction (MGD) is expanding rapidly with an increase in the number of dry eye cases and greater awareness among patients and doctors. New treatments such as thermal pulsation devices, IPL therapy, and lipid-based eye drops are increasingly popular. Demand is also fueled by factors like aging, excessive screen use, and environmental conditions. Companies are investing in research and innovation to come up with better treatment options. Telemedicine and online shopping are also making MGD treatments accessible to more people. Advanced tools are increasingly being used in more eye clinics and hospitals for early diagnosis and care. Additionally, government support and funding for eye health research are helping the market expand further.
Increasing Prevalence of Dry Eye Disease: Driving the Meibomian Gland Dysfunction
The most common cause of the increase in cases of meibomian gland dysfunction (MGD) is the rising prevalence of dry eye disease (DED) worldwide. MGD causes irritation and visual disturbance because it is one of the primary causes of evaporative dry eyes. Contemporary habits such as increased screen time, longer hours spent on digital devices, and environmental pollutants exposure have skyrocketed the number of people who claim to experience dry-eye symptoms and consequently worsen MGD. The other key driver is the aging population, as the function of the meibomian gland declines with age, leading to reduced oil secretion and gland blockages. Other factors that lead to the occurrence of this condition are worn contact lenses, some drugs such as antidepressants and antihistamines, as well as other cosmetic materials like eyelash extensions that lead to or increase the malfunction of these glands. Alongside these, autoimmune diseases and chronic inflammatory conditions like Sjogren’s syndrome, rosacea, and rheumatoid arthritis have also been known to cause problems with the meibomian glands’ health. Exposure to irritants has also increased with urbanization, increasing pollution levels, and climate change, thereby disrupting the stability of the tear film. Along with higher-awareness levels of DED and MGD, healthcare providers and pharmaceutical firms are designing early detection techniques, advanced treatments, and innovative treatments such as thermal pulsation therapy, IPL therapy, and lipid-based artificial tears. With growing risk factors and long-term concerns over MGD, the demand for proper therapies and latest research in this field is expected to increase.
Request a PDF Sample Report: https://www.imarcgroup.com/meibomian-gland-dysfunction-market/requestsample
Development of Novel Therapies and Pharmacological Treatments: Contributing to Market Expansion
The new therapies and pharmacological treatments of meibomian gland dysfunction are crucial to a growing treatment market. In fact, MGD, one of the most common causes of dry eye disease, is now increasingly recognized as an anomaly that needs to be treated by radical methods apart from mere warm compresses and eyelid cleaning. Recent advances include new drugs that are being developed for inflammation, other innovative eye treatments to improve meibum quality, unblock glands, and reduce inflammation. Treatments which focus on the replenishment of lipids and stimulation of tear production are also gaining popularity as they offer relief to patients who have long-term symptoms. New drug delivery systems, including sustained-release formulations and eye drops containing active ingredients, are also increasing patient compliance while offering better long-term results. Advanced devices aiding in gland expression and thermal therapy, in addition to pharmaceutical therapy, offer an integrated approach in the management of MGD. As more treatments are approved from clinical trials and become available, the market is becoming more varied for the treatment of MGD. With increasing awareness of the MGD impact on eye health and continued research, investment in new treatments is rapidly picking up. This is likely to continue driving market growth, offering more tailored treatment options and expanding accessibility for patients with MGD.
Buy Full Report: https://www.imarcgroup.com/checkout?id=7477&method=809
Emerging Therapies in Meibomian Gland Dysfunction Market
AZR MD 001: Azura Ophthalmics
AZR-MD-001, an investigational treatment developed by Azura Ophthalmics, is an ophthalmic ointment aimed at addressing Meibomian Gland Dysfunction (MGD). When applied to the lower eyelid, it uses selenium sulfide to dissolve abnormal keratin, clear blocked glands, and improve the quality and flow of meibum. This innovative treatment approach is designed to restore the normal function of the glands and alleviate the symptoms linked to MGD.
CBT006: Cloudbreak therapeutics
CBT-006 is a Cloudbreak Therapeutics investigational eye drop formulation, which is meant to treat Meibomian Gland Dysfunction. It does this by dissolving cholesterol deposits at the orifice of the meibomian gland and aims to enhance the quality of meibum and gland health. This treatment is intended to restore the lipid layer of the tear film to alleviate symptoms related to MGD.
Drug Name | Company Name | MOA | ROA |
AZR MD 001 | Azura Ophthalmics | Proteolysis | Topical |
CBT006 | Cloudbreak therapeutics | Cholesterol modulators | Topical |
Detailed list of emerging therapies in Meibomian Gland Dysfunction is provided in the final report…
Leading Companies in the Meibomian Gland Dysfunction Market:
The market research report by IMARC encompasses a comprehensive analysis of the competitive landscape in the market. Across the worldwide meibomian gland dysfunction market, there are several leading companies developing integrated platforms to augment the management of meibomian gland dysfunction. Leading players include Azura Ophthalmics, and others. Companies like these are innovating in the meibomian gland dysfunction market through research, diagnostic tools, and new product development to cater to the increasing demand for meibomian gland dysfunction.
Key Players in Meibomian Gland Dysfunction Market:
The key players in the meibomian gland dysfunction market who are in different phases of developing different therapies are Cloudbreak therapeutics, AxeroVision, Novoxel, Santen Pharmaceutical, Azura Ophthalmics, and others.
Regional Analysis:
The major markets for meibomian gland dysfunction include the United States, Germany, France, the United Kingdom, Italy, Spain, and Japan. According to estimates from IMARC, the United States house the largest patient pool afflicted with meibomian gland dysfunction, besides harboring the largest market for its treatment. The diagnosis and treatment of meibomian gland dysfunction have witnessed various recent advances. Meibography is one of the new imaging techniques that allows the meibomian glands to be visualized better. The condition can now be diagnosed with ease. In addition, newer treatments, like intense pulsed light (IPL) therapy and thermal pulsation systems, are increasingly gaining recognition as effective treatments for gland dysfunction. There is also growing research on newer medications like anti-inflammatory drugs and omega-3 supplements, which can reduce the symptoms of this condition. Growing in importance is considering how lifestyle variables, such as prolonged screen times, may further contribute to more severe MGD.
Recent Developments in Meibomian Gland Dysfunction Market:
· In November 2024, Novoxel revealed that the U.S. Food and Drug Administration (FDA) had approved devices like Tixel for treating Meibomian Gland Dysfunction (MGD). Tixel works by using thermal energy to stimulate the meibomian glands, improving their function and easing dry eye symptoms.
· In June 2024, Santen Pharmaceutical initiated a Phase 2a clinical trial in Japan to evaluate the efficacy and safety of STN1010905, an ophthalmic suspension designed to enhance meibomian gland function through mTOR inhibition. This randomized, evaluator-masked, placebo-controlled, parallel-group, multicenter study aims to assess the potential of STN1010905 in treating Meibomian Gland Dysfunction (MGD).
· In June 2024, Azura Ophthalmics revealed that the first patient has been enrolled in the ASTRO study, a Phase 3 clinical trial aimed at evaluating the safety and effectiveness of AZR-MD-001 in individuals displaying clinical signs and symptoms of Meibomian Gland Dysfunction (MGD).
Key information covered in the report.
Base Year: 2024
Historical Period: 2019-2024
Market Forecast: 2025-2035
Countries Covered
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the meibomian gland dysfunction market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the meibomian gland dysfunction market
- Reimbursement scenario in the market
- In-market and pipeline drugs
Competitive Landscape:
This report offers a comprehensive analysis of current meibomian gland dysfunction marketed drugs and late-stage pipeline drugs.
In-Market Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Ask Our Expert & Browse Full Report with TOC: https://www.imarcgroup.com/meibomian-gland-dysfunction-market/toc
IMARC Group Offer Other Reports:
Pharmacovigilance Market: The global pharmacovigilance market size was valued at USD 8.5 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 16.3 Billion by 2033, exhibiting a CAGR of 7.5% from 2025-2033.
Ambulance Services Market: The global ambulance services market size reached USD 58.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 116.8 Billion by 2033, exhibiting a growth rate (CAGR) of 7.22% during 2025-2033.
3D Cell Culture Market: The global 3D cell culture market size was valued at USD 2,643.1 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 7,819.7 Million by 2033, exhibiting a CAGR of 12.69% during 2025-2033.
Patient Engagement Solutions Market: The global patient engagement solutions market size reached USD 41.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 140.4 Billion by 2033, exhibiting a growth rate (CAGR) of 14.46% during 2025-2033.
Contact Lenses Market: The global contact lenses market size reached USD 9.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 14.6 Billion by 2033, exhibiting a growth rate (CAGR) of 4.98% during 2025-2033.
Wearable Injectors Market: The global wearable injectors market size reached USD 8.7 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 26.8 Billion by 2033, exhibiting a growth rate (CAGR) of 12.69% during 2025-2033.
Contact US
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Phone Number: - +1 631 791 1145, +91-120-433-0800